HCW Biologics
HCWB | NASDAQ
$0.80
+$0.03 (+3.48%)
At close: Nov 16, 2026, 4:00 PM ET
$0.77
-$0.03 (-3.61%)
After-hours:
Nov 16, 2026, 6:56 PM ET
HCW Biologics Company Profile
Company profile explainedCompany Profile
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Key Executives
| Name | Position |
|---|---|
| Hing C. Wong | Founder, Chief Executive Officer, Director & Secretary |
| Rebecca Byam | Chief Financial Officer |
| Lee D. Flowers | Senior Vice President of Business Development |
| Nicole Valdivieso | Vice President of Legal Affairs |
| Peter Rhode | Chief Scientific Officer & Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 09, 2026 | EFFECT | Filing |
| Oct 08, 2026 | D | Filing |
| Oct 02, 2026 | S-1 | Filing |
| Oct 01, 2026 | DEF 14A | Filing |
| Sep 24, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 8-K | Current Report |
| Sep 09, 2026 | PRER14A | Filing |
| Sep 08, 2026 | 8-K | Current Report |
| Sep 08, 2026 | PRE 14A | Filing |
| Aug 31, 2026 | EFFECT | Filing |
HCW Biologics
| Country | United States |
| IPO Date | Jul 20, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Hing C. Wong |
Contact Details
2929 North Commerce Parkway Miramar,
Florida 33025 United States
Stock Details
| Ticker Symbol | HCWB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001828673 |
| CUSIP Number | 40423R303 |
| ISIN Number | US40423R3030 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove HCWB